Neuca

Neuca Equity Ratio

The Equity Ratio of Neuca (NEU.WA) as of Oct 21, 2026 is 16.70 %. In the previous year, Equity Ratio was 20.67 % — a change of -19.24% (lower).

Equity Ratio

16.70 %

YoY

-19.24%

Last updated:

Equity Ratio of Neuca is 2025 16.70 % . Equity Ratio of Neuca was 2024 20.67 % . It decreases by -19.24% lower compared to the previous year.

The Neuca Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
20.98 PLN
Jan 1, 2019
18.89 PLN
Jan 1, 2020
21.25 PLN
Jan 1, 2021
20.58 PLN
Jan 1, 2022
18.19 PLN
Jan 1, 2023
19.14 PLN
Jan 1, 2024
20.67 PLN
Jan 1, 2025
16.70 PLN
The Neuca Equity Ratio history
YEAREquity RatioYoY
16.70 %-19.24%
20.67 %+8.03%
19.14 %+5.21%
18.19 %-11.63%
20.58 %-3.13%
21.25 %+12.50%
18.89 %-9.97%
20.98 %-5.44%
22.18 %+3.16%
21.51 %+11.54%
19.28 %+8.18%
17.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

Equity Ratio of Neuca is 16.70 % in 2025.

Equity Ratio of Neuca changed from 20.67 % to 16.70 %, representing a -19.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Neuca since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Neuca with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Neuca

All Key Metrics — Neuca